Key points
- First NervAlign® Nerve Cuff cases completed in Hong Kong
- First surgical case completed in Malaysia
- Record FY26 sales of $510,357, up 88% on the prior year
Full summary
ReNerve Ltd, an Australian medical device company, has successfully completed the first surgical cases using its NervAlign® Nerve Cuff in Hong Kong and Malaysia. These milestones follow the company's expanded regulatory approval in the region and the appointment of exclusive distributors. In Hong Kong, the cases represent the first commercial use of NervAlign® in the territory, while in Malaysia, the first case was performed at Thomson Hospital in Kuala Lumpur. The company's US business continues to expand, with 25 distribution partners, purchasing approvals across the US Department of Defense and Veterans Affairs healthcare systems, and growing uptake of the Empliq® human tissue range alongside NervAlign®. ReNerve now has commercial activity across seven jurisdictions.
Guidance
FY26 sales of $510,357, up 88% on the prior year
Outlook
ReNerve intends to provide further updates as the company advances commercial entry into Indonesia, the Philippines, and India.